Anthem Biosciences Ltd
ANTHEM
Company Profile
Business description
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
Contact
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1
Bommasandra
BangaloreKA560 099
INDT: +91 8066724000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,245.80 | 18.07 | -0.22% |
| DAX 40 | 23,806.99 | 273.64 | -1.14% |
| Dow JONES (US) | 48,301.90 | 391.98 | 0.82% |
| FTSE 100 | 10,603.48 | 5.40 | -0.05% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,810.76 | 175.76 | 0.78% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,829.52 | 46.71 | 0.69% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |